NBIX - Neurocrine Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
79.91
-0.92 (-1.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close80.83
Open80.97
Bid0.00 x 1000
Ask0.00 x 800
Day's Range79.06 - 81.21
52 Week Range64.72 - 126.98
Volume671,077
Avg. Volume839,570
Market Cap7.295B
Beta (3Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1995-12-29
1y Target EstN/A
Trade prices are not sourced from all markets
  • Markit9 days ago

    See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

    Neurocrine Biosciences Inc NASDAQ/NGS:NBIXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NBIX are favorable, with net inflows of $3.55 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)
    Insider Monkey16 days ago

    Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT

    Q1 2019 Neurocrine Biosciences Inc Earnings Call

  • Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount?
    Simply Wall St.27 days ago

    Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount?

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Neurocrine...

  • Zacks29 days ago

    Not Ready to Rally

    Not Ready to Rally

  • Zacks2 months ago

    Trade Anxieties Return with a Vengeance

    Trade Anxieties Return with a Vengeance

  • Neurocrine Biosciences Has Robust Late-Stage Pipeline
    Market Realist2 months ago

    Neurocrine Biosciences Has Robust Late-Stage Pipeline

    Is Neurocrine Biosciences an Attractive Pick after Q1 Results?(Continued from Prior Part)Opicapone in Parkinson’s DiseaseIn its first-quarter earnings conference call, Neurocrine Biosciences (NBIX) highlighted plans to submit an NDA (new drug

  • What Are Analysts Recommending for NBIX after Q1 Results?
    Market Realist2 months ago

    What Are Analysts Recommending for NBIX after Q1 Results?

    Is Neurocrine Biosciences an Attractive Pick after Q1 Results?Stock price movementsNeurocrine Biosciences (NBIX) reported first-quarter results on April 29. The company reported total revenues of $138.40 million, a YoY rise of 94.70%. Posted

  • Benzinga2 months ago

    The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...

  • Neurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Neurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call Transcript

    NBIX earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Neurocrine: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of $1.12 per share. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss ...

  • Analysts point to potential Biogen M&A options after Alzheimer's failure
    American City Business Journals2 months ago

    Analysts point to potential Biogen M&A options after Alzheimer's failure

    Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.

  • Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ?

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 15 S&P 500 stocks among hedge funds at […]

  • Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company?
    Simply Wall St.2 months ago

    Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Neurocrine Biosciences, Inc. (NASDAQ:NBIX), with a market cap of US$7.7b, are often out of the spotlight. While they are less talk...

  • Analysts Raise Neurocrine Biosciences’ Target Price in March
    Market Realist3 months ago

    Analysts Raise Neurocrine Biosciences’ Target Price in March

    Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 26.66% for Neurocrine Biosciences (NBIX) based on the company’s

  • 2 Biotech Takeout Targets Perfect for Biogen
    Motley Fool3 months ago

    2 Biotech Takeout Targets Perfect for Biogen

    A midsize acquisition seems imminent, and these two would fit like a glove.

  • Sage Stock Pops on FDA Approval for Postpartum Depression Drug
    InvestorPlace3 months ago

    Sage Stock Pops on FDA Approval for Postpartum Depression Drug

    Sage Therapeutics (NYSE:SAGE) is popped yesterday on FDA approval of its postpartum depression drug -- the first of its kind. So far, SAGE stock is up 3%, but this on the back of a more than 70% run up year-to-date in anticipation of the news.Source: Shutterstock Postpartum depression is a sometimes life-threatening condition that can happen before or after a woman gives birth to a child. In serious cases, she may harm herself or her child as a result. It is estimated that as many as one in nine women who have recently given birth suffer from postpartum depression, but it is a little talked about condition, so up to half of cases go unreported. But now there is a specific treatment. Zulresso was approved as an IV treatment to be administered in a certified healthcare facility over 2.5 days. With no other drug on the market to treat postpartum depression, Sage has no competition to worry about. And with a market cap of $7.8 billion -- lower than the addressable market potential for this treatment -- biotech investors cannot afford to ignore SAGE stock. Efficacy of ZulressoIn two clinical studies where participants received Zulresso or placebo, those who were treated showed an improvement of depressive symptoms compared to the placebo group.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSage Therapeutics recently raised $500 million through a SAGE stock offering on February 25. This cash infusion will give the company the capital it needs to roll out Zulresso following its approval. Sage Is Sitting on Plenty of CashIn its fourth quarter, SAGE lost $3.38 per share on revenue of just $0.28 million. But it ended the period with $922.8 million in cash, cash equivalents and marketable securities. This is up from $518.8 million at the end of 2017. Sage's management said it has enough cash on hand to fund expenses until the second half of next year (2020).Sage accelerated its R&D activity, which increased such expenses to $88.8 million, up from $50.9 million. IT spent $282.1 million in R&D for the full year 2018. Sage spent more on discovery efforts associated with identifying new clinical candidates, along with additional indications in its three CNS franchises. After the FDA approved Zulresso, R&D costs associated with Phase 3 clinical development may shift to marketing and G&A spend instead. Ahead of the launch, Sage spent $201.4 million in G&A costs, up sharply from $62.9 million last year. Sage's Full PipelineWithin Sage Therapetics' pipeline are more promising drugs. For example, SAGE-217 is being tested for efficacy in treating major depressive disorder, postpartum depression, biopolar depression and insomnia. Meanwhile, SAGE-324 has an indication for Parkinson's Disease, Essential Tremor and Epileptiform Disorders. The Bottom Line on Sage StockEven after Sage stock's recent rally, 10 analysts who follow the stock have an average12-month target price of $198 -- according to Tipranks. That's more than 25% upside. Biotech investors who are looking for similar stocks could consider Neurocrine Bio (NASDAQ:NBIX) or Zogenix (NASDAQ:ZGNX). * 5 Cloud Stocks to Help Your Portfolio Fly Sage Therapeutics has a promising drug that will not face any competition. Markets already expect strong sales for Zulresso. The company has a strong cash balance and plenty of more drugs in the pipeline. For these reasons, biotech investors should take a serious look at SAGE stock.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Sage Stock Pops on FDA Approval for Postpartum Depression Drug appeared first on InvestorPlace.

  • CTLT or NBIX: Which Is the Better Value Stock Right Now?
    Zacks3 months ago

    CTLT or NBIX: Which Is the Better Value Stock Right Now?

    CTLT vs. NBIX: Which Stock Is the Better Value Option?

  • Zacks4 months ago

    Stocks Slide for Third Straight Day

    Stocks Slide for Third Straight Day

  • Why These 2 Biotech Stocks Might Be Next On The Takeover List
    Investor's Business Daily4 months ago

    Why These 2 Biotech Stocks Might Be Next On The Takeover List

    Acadia Pharmaceuticals and Neurocrine Biosciences stand out as potential takeover candidates among biotech stocks, an analyst said Friday. Both are working on central nervous system drugs.